Naloxone is used to revive a person who is overdosing on opiates, such as heroin.
The FDA also reported that there have been no reports of adverse side effects from using a recalled product.
According to the Food and Drug Administration, the opioid overdose antidote Naloxone, or Narcan, has been recalled by its maker.
The risk is reduced by the possibility of detection, as the labeling contains a clear statement directing a visual inspection of the product for particulate matter and discoloration.
Exposure to these particulates could have adverse health effects on users of Naloxone.
Hospira has notified retailers, hospitals and distributors of the recall to arrange for returns and exchanges on any impacted product.
Below are the two lots that have been recalled.
When administered, Naloxone can quickly restore normal respiration to someone whose breathing has slowed or stopped due to opioids.
Naloxone is sold for IV, intramuscular, and subcutaneous use.
The CDC released a report in March that shows that 115 Americans are dying every day from the opioid epidemic. Nationwide, an estimated 60,000 people in the USA died from drug overdoses in 2016, more than gunshots or traffic accidents.
Hospira has recalled the drug from single-use sterile cartridges which have been distributed to hospitals, distributors and wholesalers in the US, Guan and Puerto Rico during February 2017 to February 2018.
Some of the states that were hardest hit by the opioid epidemic include West Virginia, New Hampshire, Ohio, the District of Columbia, Maryland, and MA.